Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

📆 11/10/2023 04:59:00
📰 MarketWatch

⏱ Reading Time:
16 sec. here
2 min. at publisher
📊 Quality Score:
News: 10%
Publisher: 97%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: @MKTWgoldstein.

The trial success of Novo Nordisk’s hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Fresenius Medical Care shares XE:FME FMS slumped 23%, and shares of its part owner Fresenius XE:FRE lost 12%, after Novo Nordisk halted a trial of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease early because of its efficacy.

Escrever Comentário

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Food Stocks Are Falling. Don't Blame Ozempic.Packaged-food stocks are in the red as of late, and it may indicate that consumers are shifting to fresh produce, meat, deli, and bakery products.
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »